Driehaus Capital Management LLC filed a Schedule 13G with the SEC on November 16, 2026, disclosing a beneficial ownership position in Design Therapeutics, Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Driehaus Capital Management LLC reported ownership of 3,650,681 shares of Design Therapeutics common stock.
  • Percent of class: The reported position represents 5.83% of the outstanding common stock.
  • Voting power: Driehaus reported 0 shares with sole voting power and 3,650,681 shares with shared voting power.
  • Dispositive power: Driehaus reported 0 shares with sole dispositive power and 3,650,681 shares with shared dispositive power.
  • Nature of holdings: According to the filing, the shares are held by numerous clients on a fully discretionary basis in accounts managed by Driehaus Capital Management LLC.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.

Driehaus Capital Management Crosses 5% Threshold in Design Therapeutics

Driehaus Capital Management LLC, a Delaware-organized investment adviser headquartered at 25 East Erie Street, Chicago, Illinois 60611, disclosed in a Schedule 13G filed November 16, 2026, that it beneficially owns 3,650,681 shares of common stock in Design Therapeutics, Inc. (NASDAQ:DSGN). The filing was triggered by an event dated September 30, 2026, and was signed by Janet McWilliams, General Counsel of Driehaus Capital Management LLC.

According to the filing, all 3,650,681 shares are held with shared voting power and shared dispositive power, with no shares attributed to sole voting or sole dispositive power. The filing states that "the shares reported by Driehaus Capital Management LLC (DCM) are held by numerous clients on a fully discretionary basis in accounts managed by DCM," and that "securities held in these clients' accounts are included in this report to reflect that DCM may have voting power and has dispositive power."

The filing further states that, to the best of DCM's knowledge, none of the referenced clients "have the right to receive dividends or direct proceeds from the sale of interests relating to more than 5% of the class." Design Therapeutics, Inc. is based at 6005 Hidden Valley Road, Suite 110, Carlsbad, CA 92011. The CUSIP number for the common stock covered by this filing is 25056L103. The filing certifies the securities were acquired and are held in the ordinary course of business and were not acquired for the purpose of changing or influencing control of the issuer.

What Was Disclosed

Driehaus Capital Management LLC disclosed beneficial ownership of 3,650,681 shares, or 5.83%, of Design Therapeutics, Inc. common stock as of September 30, 2026, with all shares held on a shared voting and shared dispositive basis on behalf of discretionary client accounts.